2025-10-17 - Analysis Report
Okay, here's an analysis of Natera Inc. (NTRA) based on the data you provided, structured into sections for clarity.

## Natera Inc. (NTRA) Analysis

**Company Overview:** Natera Inc. is a diagnostics company specializing in cell-free DNA testing, particularly in the areas of reproductive health, oncology, and organ health.

### 1. Performance vs. S&P 500 (VOO)

*   **NTRA Cumulative Return:** 78.62%
*   **VOO Cumulative Return:** 96.69%
*   **Absolute Divergence:** -23.4
*   **Relative Divergence:** 24.7 (Indicates NTRA is positioned in the lower quartile of its historical divergence range compared to VOO)

**Analysis:** NTRA has underperformed the S&P 500 (VOO) over the specified period, with a cumulative return difference of -23.4%. The relative divergence of 24.7 suggests that NTRA's underperformance, while significant, is not at its worst historical level compared to VOO.

**Alpha, Beta Analysis Table:**

| Year       | CAGR    | MDD   | Alpha   | Beta   | Cap(B) |
|------------|---------|-------|---------|--------|--------|
| 2015-2017  | -10.0%  | 70.1% | -34.0%  | -0.2   | 1.3    |
| 2016-2018  | 22.0%   | 80.0% | 6.0%    | 0.1    | 2.0    |
| 2017-2019  | 50.0%   | 80.0% | 28.0%   | 1.0    | 4.8    |
| 2018-2020  | 186.0%  | 80.5% | 163.0%  | 1.1    | 14.3   |
| 2019-2021  | 96.0%   | 80.5% | 49.0%   | 1.6    | 13.4   |
| 2020-2022  | -77.0%  | 80.5% | -76.0%  | 0.1    | 5.8    |
| 2021-2023  | -194.0% | 76.6% | -195.0% | -1.1   | 9.0    |
| 2022-2024  | 8.0%    | 76.6% | -13.0%  | -1.2   | 22.7   |
| 2023-2025  | 106.0%  | 76.6% | 45.0%   | 0.1    | 24.8   |

**Analysis:**

*   **CAGR:** Wide range of annual growth rates, with significant volatility. Recent periods (2021-2023) show substantial losses, but 2023-2025 shows recovery.
*   **MDD:** Consistently high Maximum Drawdown, indicating significant risk.
*   **Alpha:** Fluctuates significantly, indicating periods of both outperformance and underperformance relative to the market. The recent period shows a positive trend.
*   **Beta:** Varies, suggesting NTRA's correlation with the market has changed over time. Note the negative betas in more recent periods.
*   **Cap:** The market capitalization has generally increased over time.

### 2. Recent Price Action

*   **Current Price:** 172.81
*   **Last Market Price:** 180.54
*   **Previous Close:** 179.42
*   **Change:** 0.62
*   **5-Day Moving Average:** 171.72
*   **20-Day Moving Average:** 169.10
*   **60-Day Moving Average:** 160.63

**Analysis:**

The recent market price of 180.54 with a positive change of 0.62 indicates a slight upward movement.
The stock price is currently above all three moving averages (5, 20, and 60 days), suggesting a short-term and medium-term upward trend.

### 3. Market Risk Indicators

*   **MRI:** 0.8 (Medium Investment Recommended)
*   **RSI:** 64.55 (Approaching overbought territory)
*   **PPO:** 0.28 (Positive, indicating a slight upward trend)
*   **Hybrid Signal:** Buy 100% (Very Safe - MRI: 0.90)
*   **Delta Previous Relative Divergence (20 days):** 3.7 (Positive, Short-term increase)
*   **Expected Return:** -143.9% (Indicates significant underperformance relative to S&P 500 in the long term, if investing at current market conditions)

**Analysis:**

*   The MRI suggests a medium investment recommendation.
*   The RSI is approaching overbought levels, indicating potential for a pullback.
*   The PPO is positive, suggesting the stock price is above its moving averages.
*   The Hybrid Signal suggests a strong buy signal.
*   The positive change in recent market price from 179.42 to 180.54 suggests the stock is on an upward trend.
*   The negative expected return is a major concern, indicating potential underperformance compared to the S&P 500 in the long term.

### 4. Recent News & Significant Events

*   **Fast Company Recognition:** Natera named to Fast Company’s Next Big Things in Tech List.
*   **Liberty All-Star® Growth Fund Update:** September 2025 Monthly Update.
*   **Signatera Platform Study:** Bull Case for Natera (NTRA) could change following breakthrough study results for Signatera Platform.
*   **Signatera Validation Study Published:** Superior Prognostic Value in Testicular Cancer.
*   **Investor Call:** Natera to Host Investor Call on October 23, 2025 to Discuss ESMO Findings.
*   **Valuation Analysis:** Natera (NTRA) Valuation: Exploring Upside as Investors Weigh Recent Performance and Long-Term Potential.

**Analysis:** The news is mixed. Recognition in Fast Company and positive study results for the Signatera platform are bullish signals. The upcoming investor call could be a catalyst for price movement. However, the valuation analysis suggests investors are still weighing the company's long-term potential, so more research is needed.

### 4-2. Analyst Opinions

*   **Consensus:** Buy
*   **Mean Rating:** 1.53 (~Buy)
*   **Opinions:** 19
*   **Target Price (avg/high/low):** 193.95 / 235.00 / 37.00

**Analysis:** The analyst consensus is generally positive with a "Buy" rating and an average target price significantly above the current price, suggesting potential upside. However, the large range between the high and low target prices (37.00/235.00) indicates considerable uncertainty among analysts regarding the stock's future performance.

### 5. Recent Earnings Analysis

| 날짜       | EPS    | 매출      |
|------------|--------|-----------|
| 2025-08-08 | -0.74  | 0.55 B$   |
| 2025-05-09 | -0.5   | 0.50 B$   |
| 2024-11-12 | -0.26  | 0.44 B$   |
| 2024-08-09 | -0.3   | 0.41 B$   |
| 2025-08-08 | -0.3   | 0.41 B$   |

**Analysis:**

*   **EPS:** Natera is currently unprofitable, as evidenced by the negative EPS values. Although still negative, there was a positive trend of rising EPS from 2024-08-09(-0.3) to 2024-11-12 (-0.26)
*   **Revenue:** Revenue shows a general upward trend over the past year, indicating growth in the company's sales. The most recent quarter has highest sales of 0.55B.

### 6. Financial Information

**Revenue and Profitability:**

| Quarter      | Revenue   | Profit Margin |
|--------------|-----------|---------------|
| 2025-06-30   | $0.55B    | 63.41%        |
| 2025-03-31   | $0.50B    | 63.12%        |
| 2024-12-31   | $0.48B    | 62.94%        |
| 2024-09-30   | $0.44B    | 61.79%        |
| 2024-06-30   | $0.41B    | 58.83%        |

**Analysis:**

*   **Revenue:** Consistently increasing revenue over the last five quarters indicates strong business growth.
*   **Profit Margin:** The profit margin has been consistently high and increasing, indicating strong operational efficiency.

**Capital and Profitability:**

| Quarter      | Equity    | ROE      |
|--------------|-----------|----------|
| 2025-06-30   | $1.25B    | -8.10%   |
| 2025-03-31   | $1.24B    | -5.40%   |
| 2024-12-31   | $1.20B    | -4.50%   |
| 2024-09-30   | $0.88B    | -3.60%   |
| 2024-06-30   | $0.84B    | -4.48%   |

**Analysis:**

*   **Equity:** The company's equity has been steadily increasing, suggesting financial stability and growth.
*   **ROE:** The negative ROE indicates that the company is not generating profits from its equity. However, similar to the EPS, ROE has been increasing from 2024-06-30 (-4.48%) to 2024-09-30 (-3.60%)
### 7. Overall Assessment

Natera (NTRA) presents a mixed investment picture:

*   **Positive Signals:** Increasing revenue, improving profit margins, growth in equity, and analyst buy ratings suggest potential upside. The recent positive news regarding the Signatera platform and inclusion in Fast Company's list are bullish indicators. The recent price action is also positive, with the stock trading above its moving averages.
*   **Negative Signals:** The company is currently unprofitable (negative EPS and ROE), and has significantly underperformed the S&P 500, reflected in the negative expected return. High Maximum Drawdown values in the past highlight the stock's high risk.
*   **Overall:** NTRA appears to be a high-growth, high-risk stock. The company shows promise with its innovative technology and increasing revenue, but profitability remains a concern. Given the positive analyst ratings and recent price momentum, NTRA may be suitable for investors with a high-risk tolerance and a long-term investment horizon. However, potential investors should carefully consider the company's lack of current profitability and high volatility before investing.
